Merck Emend Drug Interaction Studies Advised By Cmte., Approval Supported

Merck's Emend should be studied in combination with CYP3A4 substrate chemotherapy drugs for potential drug-drug interactions, FDA's Gastrointestinal Drugs Advisory Committee agreed during its March 6 review